← ANALYST RATINGS · TIPRANKS

MapLight Therapeutics, Inc. (MPLT): analyst forecast and price target

$7.70 −3.99% close 16.10.26 · market cap $446M · General · Biotechnology IWM 0.01%
Price targets and ratings of

Analyst consensus

Moderate Buy

7 Buy3 Hold0 Sell

Ratings of 10 analysts in the last 3 months

12-month forecast

$26.00+237.7% upside

Based on 10 price targets given in the last 3 months, the average target is $26.00, the highest $43.00, the lowest $13.00. The average is +237.7% from the last price of $7.70.

$10.00$20.00$30.00$40.00Jan 26AprJulOctJan 27AprJulOctHigh$43.00Average$26.00Low$13.00
Highest target $43.00 Average target $26.00 Lowest target $13.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% Guggenheim — Hold — Initiated 05.10.26on TipRanks Oct 6 05:45 −6.2%next day +3.9% · 5 days −7.7%
Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% Needham $45.00 → $43.00−4.4% Buy +458.4% Assigned 31.08.26on TipRanks 07:20 +3.2%next day +3.3% · 5 days +7.7%
Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% Morgan Stanley $21.00 Hold +172.7% Assigned 17.08.26on TipRanks 08:55 −3.8%next day +5.8% · 5 days +2.2%
Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% LifeSci Capital $37.00 Buy +380.5% Reiterated 14.08.26on TipRanks 10:35 +1.7%next day −3.8% · 5 days −3.2%
Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% BMO Capital $46.00 → $20.00−56.5% Buy +159.7% Reiterated 13.08.26on TipRanks Aug 14 08:15 +1.1%next day +1.7% · 5 days −1.1%
Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% UBS $52.00 → $13.00−75.0% Hold +68.8% Downgrade 11.08.26on TipRanks Aug 10 06:35 +0.1%next day −1.3% · 5 days −7.6%
Unknown Analyst Jefferies $25.00 Buy +224.7% Reiterated 30.07.26on TipRanks 13:38 −8.3%next day −7.9% · 5 days −9.0%
Adam Vogel★★★★★★★★★★#1113 · hits 79% · avg +38.0% Craig-Hallum $40.00 → $25.00−37.5% Buy +224.7% Reiterated 28.07.26on TipRanks 09:25 +24.0%next day +23.6% · 5 days +1.0%
Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% H.C. Wainwright $45.00 → $26.00−42.2% Buy +237.7% Reiterated 28.07.26on TipRanks 06:10 +24.0%next day +23.6% · 5 days +1.0%
Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% Canaccord Genuity $43.00 → $24.00−44.2% Buy +211.7% Reiterated 27.07.26on TipRanks Jul 24 06:55 +3.7%next day −72.9% · 5 days −65.5%
Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% Raymond James $46.00 Buy +497.4% Initiated 25.06.26on TipRanks Jun 24 16:35 +4.1%next day +4.9% · 5 days +14.6%
Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% Stifel Nicolaus $28.00 → $36.00+28.6% Buy +367.5% Reiterated 02.06.26on TipRanks 06:40 −8.3%next day +4.4% · 5 days +10.0%
Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% TD Cowen — Buy — Reiterated 14.05.26on TipRanks 17:45 −0.7%next day −7.7% · 5 days −0.8%
Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% Leerink Partners $30.00 Buy +289.6% Initiated 21.11.25on TipRanks 08:30 +4.3%next day −8.5% · 5 days −6.1%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering MapLight Therapeutics, Inc.

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Sumant Kulkarni★★★★★★★★★★Canaccord Genuity · #670
Hits 50%248 of 497 Average return +14.2%
1 year Sumant Kulkarni★★★★★★★★★★Canaccord Genuity · #670
Hits 50%248 of 497 Average return +14.2%
2 years Sumant Kulkarni★★★★★★★★★★Canaccord Genuity · #670
Hits 50%248 of 497 Average return +14.2%

Most profitable

3 months Sumant Kulkarni★★★★★★★★★★Canaccord Genuity · #670
Hits 50%248 of 497 Average return +14.2%
1 year Sumant Kulkarni★★★★★★★★★★Canaccord Genuity · #670
Hits 50%248 of 497 Average return +14.2%
2 years Sumant Kulkarni★★★★★★★★★★Canaccord Genuity · #670
Hits 50%248 of 497 Average return +14.2%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $26.00 at a price of $10.19 (+155.2%); now: $26.00 at $7.70 (+237.7%).

$10.00$20.00Sep 15Oct 1Oct 15Top analysts$24.50Average target$26.00Price$7.70

PriceAverage targetTop analysts’ target

Recommendation trend

0102030Oct 254Nov7Dec7Jan 263Feb1Mar21Apr68May714Jun13191Jul12123Aug1063Sep33Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy671312103
Buy814191260
Hold001333
Sell000000

Best top-analyst consensus in the sector · General

STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
About MapLight Therapeutics, Inc.
  • CEO: Christopher A. Kroeger
  • Employees: 133
  • 800 Chesapeake Drive, Redwood City, CA, 94063, US
  • www.maplightrx.com

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.

Data from the stock’s TipRanks forecast page, read 16 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗